Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (Weighted Average) (2021 - 2025)

Lyra Therapeutics has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $1.6 million for Q4 2025, up 19.29% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 19.29% YoY), and the annual figure for FY2025 was $1.6 million, up 19.29%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.6 million at Lyra Therapeutics, down from $1.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for LYRA hit a ceiling of $64.0 million in Q1 2024 and a floor of $200612.0 in Q4 2023.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $13.0 million (2021), compared with a mean of $17.5 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 549.15% in 2024, while the deepest fall reached 97.72% in 2024.
  • Lyra Therapeutics' Shares Outstanding (Weighted Average) stood at $13.0 million in 2021, then tumbled by 61.5% to $5.0 million in 2022, then tumbled by 95.99% to $200612.0 in 2023, then soared by 549.15% to $1.3 million in 2024, then increased by 19.29% to $1.6 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.